Todd Levine

Todd Levine M.D.

Clinical Director of Adult Neurosciences
Neurogenomics Division

Todd Levine M.D.

Todd Dylan Levine, MD received his medical degree from Duke University in Durham, North Carolina. He completed a residency in Neurology and a Fellowship in Neuromuscular Disease at Washington University School of Medicine in St. Louis, Missouri. He has been a specialist in Neuromuscular disorders for the past 20 years. He is the Director of the Neurology Department at Honor Health in Phoenix Arizona. 

As part of this practice he was  the founder of the multi-disciplinary ALS Clinic. He was also one of the founders of Corinthian Reference Labs and Cutaneous Neurodiagnostics, national reference labs dedicated to using skin biopsies for diagnosing neurologic disorders such as Parkinson’s Disease and Alzheimers Disease. 

Dr. Levine is board certified by the American Board of Psychiatry and Neurology and the American Board of Electrodiagnostic Medicine. He is a fellow of the American Association of Neuromuscular and Electrodiagnostic Medicine and a member of the American Academy of Neurology. He is the past Chairman of the Neuromuscular division of the American Academy of Neurology and the Arizona State Liason for the American Academy of Neuroelectrodiagnostic Medicine. Dr. Levine conducts extensive research in diseases of the nerve and muscle. He has published his findings in numerous peer-reviewed journals and lectures both nationally and internationally on these disorders.

Freeman, R. et al, Idiopathic distal sensory polyneuropathy: ACTTION diagnostic criteria. Neurology Oct 2020.

Levine TD, Kafaie J, Zeidman LA, Saperstein DS, Massaquoi R, Bland RJ, Pestronk A. Cryptogenic small fiber neuropathies: Serum autoantibody binding to trisulfated heparan disaccharide and fibroblast growth factor 3. Muscle and Nerve 2020. April; 61(4) 512-515.

Levine TD. Safety of an abbreviated transition period when switching from intravenous immunoglobulin to Eculizumab in patients with treatment-refractory myasthenia gravis. Am J Case Rep. 2019 Jul 6;20: 965-970.

Statland, JM et al. Rasagaline for amyotrophic lateral sclerosis: A randomized, controlled trial. Muscle Nerve. 2019 Feb;59(2):201-207

Levine TD, Katz JS, Barohn R, et al. Review process for IVIG treatment: Lessons learned from Insights neuropathy study. Neurol Clin Pract. 2018; Oct 8(5) 429-436.

Levine, TD. Small fiber neuropathy: Disease classification beyond pain and burning. J Cent Nerv Syst Dis 2018 Apr 18;10-14. 

Bradley WG, Miller RX, Levine TD, Stommel EW, Cox PA. Studies of environmental risk factors in amyotrophic lateral sclerosis (ALS) and a Phase I clinical trial of L-serine.  Neurotoxicity Research 2018 Jan; 33(1) 192-198

Levine, TD, Bland, RJ. Incidence of Non-amyloidogenic mutations in the transthyretin gene in patients with small fiber and autonomic neuropathy. Muscle Nerve 2018; Jan 57(1) 140-142

Levine AA, Levine TD, Clarke K, Saperstein, D. Renal and Hematologic side effects of long term immunoglobulin therapy in patients with neurologic disorders. Muscle Nerve 2017 Dec;56(6) 1173-1176.

Aggarwal R, Rider LG, Ruperto N, et al; 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative; Arthritis Rheumatol; 2017 Apr 6

Kishnani P, Tarnopolsky M, Sivakumar K, Roberts M, Dasouki M, Dimachkie M, Finanger E,   Goker-Alpan O, Guter K, Mozaffar T, Levine TD, et al. Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients when Coadministered with Alglucosidase Alfa. Molecular Therapy. Vol 25(5);2017: 1199-1208.    

Rodriguez-Leyva I, Chi-Ahumada E, Mejia M, Castanedo-Cazares J, Eng W, Saikaly S, Carrizales J, Levine TD, Norman RA, Jiminez-Capdeville M. Presence of alpha-synuclein in skin from melanoma and Parkinson’s disease patients. Movement Disorders in Clinical Practice. 2017 Jun 1;4(5) 724-732.

Levine TD and Saperstein DS editors. Small Nerves, Big Problems: A Comprehensive Guide to Small Fiber Neuropathy. Hilton Publishing. 

Levine TD, Miller RG et al. Phase I clinical trial of safety of L-serine for ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2016. Sept 2:1-5.

Levine, TD, Saperstein, D et al. HP Acthar Gel in dermatomyositis and polymyositis treatment registry. Journal of Neurological Disorders. 2016. 4:292-8

Levine TD  Statland JM,  Dimachkie, M. Emerging therapies for inflammatory myopathies. 

Boylan, K, Levine TD Lomen-Hoerth, C et al. Prospective Study of cost of care at multi-disciplinary ALS centers adhering to American Academy of Neurology ALS practice parameters. Amyotroph Lateral Scler Frontotemporal Degener 2015.; 17(1-2)

Levine, TD, Saperstein, DS. Routine use of punch biopsy to diagnose small fiber neuropathy in fibromyalgia patients. Clin Rheumatol 2015. Mar 34(3) 413-7 

Levine, TD, Saperstein D. Laboratory evaluation of peripheral neuropathy. Neurol Clin 2013 May; (31) 2: 363-376

Oddis, CV, Reed, A, Aggarwal R, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo phase trial. Arthritis Rheum. 2013 Feb; (65) 2 314-324.

Saperstein, D, Levine, TD, Levine, M and Hank, N. Usefulness of skin biopsies in the evaluation of patients with suspected small fiber neuropathy. Int J Neurosci. 2013 Jan; 123 (1) 38-41.

Levine, TD. Treating refractory dermatomyositis and polymyositis with ACTH gel: A Case Series. Drug Development Design and Therapeutics. 2012;6: 133-139.

Shefner, J, Cedarbaum, JM, Cudkowicz, ME, et al. Safety, tolerability and pharmacokinetics of a skeletal muscle activator in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2012 Sept; 13 (5): 430-8.

Levine, TD, Saperstein, D, Bowser, R, Cox, P, and Hank, N. A pilot trial of pioglitazone and Tretinoin in ALS. Neurology Research International. Vol 2012(12): 582075

Clarke, K and Levine, TD. Clinical recognition and management of amyotrophic lateral sclerosis. J Neurosci Nurs. 2011. Aug (4). 205-214.

Levine, TD, Bowser, R, Hank, N, and Saperstein, D. A pilot trial of memantine and riluzole in ALS: correlation to CSF biomarkers. Amyotrophic Lateral Sclerosis 2010 11(5); 494-6.

Saperstein, D and Levine, TD. Diagnosing small fiber neuropathy through the use of a skin biopsy. Practical Neurology. October, 2009: 36-41

Gordon, PH, Cheung YK, Levin, B et al. A novel efficient randomized selection trial comparing combinations of drug therapy for ALS. Amyotrophic lateral Sclerosis 2008:9(4): 212-22

Dunckley T, Heuntelman MJ, Craig DW et al.  Whole genome analysis of sporadic ALS. New England Journal of Medicine, 2007: 357 (8) 775-788.

Levine TD, Pestronk A, Florence J, Al-Lozi M, Lopate G, Miller T, Ramneantu I, Waheed W, Stambuk M, Stone MJ, Choksi, R. Peripheral neuropathies in waldenstrom’s macroglobulinemia. J Neurol Neurosurg Psychiatry 2006; 77:224-228.

Lopate G, Pestronk A, Al-Lozi, M et al. Peripheral neuropathy in an outpatient cohort of patients with Sjogrens syndrome. Muscle Nerve 2006: 33(5): 672-76.

Levine, TD. Rituximab in the treatment of refractory dermatomyositis. Arthritis and Rheumatism Vol 52, No 2 Feb 2005, 601-607.

Pestronk, A, Florence J, Levine TD, Al-Lozi, M, Lopate, G, Miller T, Ramneantu, I, Waheed, W, Stambuk, M Sensory exam with a quantitative tuning fork: rapid, sensitive and predictive of SNAP amplitude. Neurology. 2004 Feb 10;62(3):461-4.

L Rider, E Giannini, H Brunner, N Ruperto, A Reed, L James-Newton, T Sanghvi, M Cronin, I Garcia-de la Torre, D Isenberg, L Kagen, T Levine, I Lundberg, C Oddis, S Rutkove, K Sivakumar, Y Song, I Targoff, J Vencovsky, M Villalba, R Wortmann, S Ytterberg, P Lachenbruch, F Miller, for the International Myositis Assessment and Clinical Studies (IMACS) Group. Preliminary Definitions of Improvement for Adult Myositis.  Arthritis Rheum. 2003; 48 (suppl.): S307.

Gertz, MA, Anagnostopoulos, A, Anderson, K, Branagan, A, Frankel, S, Giralt, S, Levine, TD, Munshi, N, Rajkumar, R, and Treon S.  Treatment wecommendations in waldenstrom’s macroglobulinemia.  Seminars in Oncology Vol 30, No2 April 2003

Levine, TD. History of Dermatomyositis. Arch Neurol. 2003 May;60(5):780-2.

Pestronk, A, Florence, J, Miller,T, Choksi, R, Al-Lozi, M, Levine, TD. Treatment of IgM-antibody associated neuropathies with rituxamab. J Neurol Neurosurg Psychiatry. 2003 Apr;74(4):485-9.

Levine, TD and Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using rituxamab. Neurology 1999 52:8; 1701-1705.

Levine, TD and Pestronk, A. Methotrexate therapy for polymyositis with cytochrome oxidase negative fibers. Muscle and Nerve  21:1724-1728,1998. 

Keene, JD, Levine, TD, and Gao, FB. US Patent No. 5,525,495, Methods and composition useful in the recognition, binding, and expression of ribonucleic acids involved in cell growth, neoplasia, and immunoregulation.

Gao, FB, Carson, CC, Levine TD, and Keene, JD. Selection of a subset of mRNA’s from combinatorial 3’ UTR libraries using neuronal RNA binding protein Hel-N1, PNAS 91(23): 11207, 1994.

King, PH, Levine TD, Fremeau, RT, Keene, JD.  Mammalian homologs of  Drosophila ELAV localized to a neuronal subset can bind in vitro to the 3’ UTR of  the mRNA encoding the Id transcriptional repressor.  Journal of Neuroscience 14(11): 1943, 1994.

Levine, TD, Gao FB, King, PH, Andrews LG, Keene, JD.  Hel-N1: an autoimmune RNA binding protein with specificity for the 3’ uridylate rich untranslated regions of growth factor mRNAs. Moll. and Cell. Biol. 13 (6): 3494, 1993.

Back To Top